Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register.

Multiple sclerosis Quality control Quality indicators Real world data Register

Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 20 02 2023
accepted: 24 05 2023
medline: 23 10 2023
pubmed: 14 6 2023
entrez: 13 6 2023
Statut: ppublish

Résumé

Over the years, disease registers have been increasingly considered a source of reliable and valuable population studies. However, the validity and reliability of data from registers may be limited by missing data, selection bias or data quality not adequately evaluated or checked. This study reports the analysis of the consistency and completeness of the data in the Italian Multiple Sclerosis and Related Disorders Register. The Register collects, through a standardized Web-based Application, unique patients. Data are exported bimonthly and evaluated to assess the updating and completeness, and to check the quality and consistency. Eight clinical indicators are evaluated. The Register counts 77,628 patients registered by 126 centres. The number of centres has increased over time, as their capacity to collect patients. The percentages of updated patients (with at least one visit in the last 24 months) have increased from 33% (enrolment period 2000-2015) to 60% (enrolment period 2016-2022). In the cohort of patients registered after 2016, there were ≥ 75% updated patients in 30% of the small centres (33), in 9% of the medium centres (11), and in all the large centres (2). Clinical indicators show significant improvement for the active patients, expanded disability status scale every 6 months or once every 12 months, visits every 6 months, first visit within 1 year and MRI every 12 months. Data from disease registers provide guidance for evidence-based health policies and research, so methods and strategies ensuring their quality and reliability are crucial and have several potential applications.

Identifiants

pubmed: 37311951
doi: 10.1007/s10072-023-06876-9
pii: 10.1007/s10072-023-06876-9
pmc: PMC10264214
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4001-4011

Investigateurs

U Aguglia (U)
M P Amato (MP)
A L Ancona (AL)
B Ardito (B)
C Avolio (C)
R Balgera (R)
P Banfi (P)
V Barcella (V)
P Barone (P)
P Bellantonio (P)
A Berardinelli (A)
R Bergamaschi (R)
P Bertora (P)
M Bianchi (M)
P Bramanti (P)
V Brescia Morra (V)
G Brichetto (G)
A M Brioschi (AM)
M Buccafusca (M)
S Bucello (S)
V Busillo (V)
B Calchetti (B)
R Cantello (R)
M Capobianco (M)
F Capone (F)
L Capone (L)
D Cargnelutti (D)
M Carozzi (M)
E Cartechini (E)
G Cavaletti (G)
P Cavalla (P)
M G Celani (MG)
R Clerici (R)
M Clerico (M)
E Cocco (E)
V Torri Clerici (V)
M G Coniglio (MG)
A Conte (A)
F Corea (F)
S Cottone (S)
P Crociani (P)
F D'Andrea (F)
M C Danni (MC)
G De Luca (G)
D de Pascalis (D)
M De Riz (M)
F De Robertis (F)
G De Rosa (G)
N De Stefano (N)
M Della Corte (M)
A Di Sapio (A)
R Docimo (R)
M Falcini (M)
N Falcone (N)
S Fermi (S)
E Ferraro (E)
M T Ferrò (MT)
M Fortunato (M)
M Foschi (M)
A Gajofatto (A)
A Gallo (A)
P Gallo (P)
M Gatto (M)
P Gazzola (P)
A Giordano (A)
F Granella (F)
M G Grasso (MG)
Lme Grimaldi (L)
P Iaffaldano (P)
P Immovilli (P)
D Imperiale (D)
M Inglese (M)
R Iodice (R)
S Leva (S)
V Leuzzi (V)
A Lugaresi (A)
G Lus (G)
D Maimone (D)
L Mancinelli (L)
G T Maniscalco (GT)
G A Marfia (GA)
L Margari (L)
F Marinelli (F)
B Marini (B)
A Marson (A)
N Mascoli (N)
L Massacesi (L)
F Melani (F)
M Merello (M)
C Fioretti (C)
M Mirabella (M)
S Montepietra (S)
D Nasuelli (D)
P Nicolao (P)
L Pasquali (L)
F Passantino (F)
F Patti (F)
C Pecori (C)
M Peresson (M)
I Pesci (I)
C Piantadosi (C)
M L Piras (ML)
M Pizzorno (M)
K Plewnia (K)
C Pozzilli (C)
A Protti (A)
R Quatrale (R)
S Realmuto (S)
G Ribizzi (G)
S Rinalduzzi (S)
A Rini (A)
S Romano (S)
M Filippi (M)
M Ronzoni (M)
P Rossi (P)
M Rovaris (M)
G Salemi (G)
G Santangelo (G)
M Santangelo (M)
A Leone (A)
P Sarchielli (P)
L Sinisi (L)
D Ferraro (D)
C Solaro (C)
D Spitaleri (D)
S Strumia (S)
T Tassinari (T)
G Santuccio (G)
C Tortorella (C)
R Totaro (R)
A Tozzo (A)
G Trivelli (G)
G Turano (G)
M Ulivelli (M)
P Valentino (P)
S Venturi (S)
M Vianello (M)
M Zaffaroni (M)
R Zarbo (R)

Informations de copyright

© 2023. The Author(s).

Références

Hoeijmakers F, Beck N, Wouters MWJM, Prins HA, Steup WH (2018) National quality registries: how to improve the quality of data. J Thorac Dis 10(Suppl 29):S3490–S3499. https://doi.org/10.21037/jtd.2018.04.146
doi: 10.21037/jtd.2018.04.146 pubmed: 30510784 pmcid: 6230825
Pop B, Fetica B, Blaga ML et al (2019) The role of medical registries, potential applications and limitations. Med Pharm Rep 92(1):7–14. https://doi.org/10.15386/cjmed-1015
doi: 10.15386/cjmed-1015 pubmed: 30957080 pmcid: 6448488
EMA. Guideline on registry-based studies. European Medicines Agency. Published October 15, 2021. Accessed July 12, 2022. https://www.ema.europa.eu/en/guideline-registry-based-studies-0
Harrison DM (2014) In the clinic. Multiple sclerosis. Ann Intern Med. 160(7):ITC4–2-ITC4–18; quiz ITC4–16. https://doi.org/10.7326/0003-4819-160-7-201404010-01004
Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis. Neurology 83(3):278–286. https://doi.org/10.1212/WNL.0000000000000560
doi: 10.1212/WNL.0000000000000560 pubmed: 24871874 pmcid: 4117366
Guidelines of the Italian Society of Neurology for diagnosis and treatment of MS [published on the Italian National Institute of Health site.
Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 24(2):96–120. https://doi.org/10.1177/1352458517751049
doi: 10.1177/1352458517751049
Ghezzi A (2018) European and American guidelines for multiple sclerosis treatment. Neurol Ther 7(2):189–194. https://doi.org/10.1007/s40120-018-0112-1
doi: 10.1007/s40120-018-0112-1 pubmed: 30315481 pmcid: 6283786
Ezabadi SG, Sahraian MA, Maroufi H, Shahrbaf MA, Eskandarieh S (2022) Global assessment of characteristics of multiple sclerosis registries; a systematic review. Mult Scler Relat Disord 63:103928. https://doi.org/10.1016/j.msard.2022.103928
doi: 10.1016/j.msard.2022.103928 pubmed: 35661909
Cohen JA, Trojano M, Mowry EM, Uitdehaag BM, Reingold SC, Marrie RA (2020) Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Mult Scler Houndmills Basingstoke Engl 26(1):23–37. https://doi.org/10.1177/1352458519892555
doi: 10.1177/1352458519892555
Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55(8):671–676. https://doi.org/10.1136/jnnp.55.8.671
doi: 10.1136/jnnp.55.8.671 pubmed: 1527537 pmcid: 489202
Butzkueven H, Chapman J, Cristiano E et al (2006) MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 12(6):769–774. https://doi.org/10.1177/1352458506070775
doi: 10.1177/1352458506070775
Trojano M, Paolicelli D, Lepore V et al (2006) Italian multiple sclerosis database network. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 27(Suppl 5):S358-361. https://doi.org/10.1007/s10072-006-0694-8
doi: 10.1007/s10072-006-0694-8
Myhr KM, Grytten N, Aarseth JH (2012) The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurol Scand Suppl 195:20–23. https://doi.org/10.1111/ane.12030
doi: 10.1111/ane.12030
Flachenecker P, Buckow K, Pugliatti M et al (2014) Multiple sclerosis registries in Europe - results of a systematic survey. Mult Scler Houndmills Basingstoke Engl 20(11):1523–1532. https://doi.org/10.1177/1352458514528760
doi: 10.1177/1352458514528760
Hillert J, Stawiarz L (2015) The Swedish MS registry – clinical support tool and scientific resource. Acta Neurol Scand 132(199):11–19. https://doi.org/10.1111/ane.12425
doi: 10.1111/ane.12425 pubmed: 26046553 pmcid: 4657484
Koch-Henriksen N, Magyari M, Laursen B (2015) Registers of multiple sclerosis in Denmark. Acta Neurol Scand 132(199):4–10. https://doi.org/10.1111/ane.12424
doi: 10.1111/ane.12424 pubmed: 26046552
EMA. Patient registries. European Medicines Agency. Published September 17, 2018. Accessed July 12, 2022. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/patient-registries
Trojano M, Bergamaschi R, Amato MP et al (2019) The Italian multiple sclerosis register. Neurol Sci 40(1):155–165. https://doi.org/10.1007/s10072-018-3610-0
doi: 10.1007/s10072-018-3610-0 pubmed: 30426289
Miksad RA, Abernethy AP (2018) Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin Pharmacol Ther 103(2):202–205. https://doi.org/10.1002/cpt.946
doi: 10.1002/cpt.946 pubmed: 29214638
Gliklich RE, Leavy MB (2020) Assessing real-world data quality: the application of patient registry quality criteria to real-world data and real-world evidence. Ther Innov Regul Sci 54(2):303–307. https://doi.org/10.1007/s43441-019-00058-6
doi: 10.1007/s43441-019-00058-6 pubmed: 32072577
MedDRA. Literature | MedDRA. Accessed July 12, 2022. https://www.meddra.org/literature
Ministero della Salute. Manuale ICD-9-CM versione italiana 2007. Accessed July 13, 2022. https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2251
Eurocat. European platform on rare disease registration. Accessed July 12, 2022. https://eu-rd-platform.jrc.ec.europa.eu
Farmadati. Farmadati Italia - Banca Dati del Farmaco, Parafarmaco e Dispositivo Medico. Accessed July 12, 2022. https://www.farmadati.it/
AISM. SOP Manual of Procedures (MOP) for Italian multiple sclerosis register and related disorders (Version 01–15/07/2021). Accessed July 12, 2022. https://registroitalianosm.it/index.php?page=docprogetto
Glaser A, Stahmann A, Meissner T et al (2019) Multiple sclerosis registries in Europe - an updated mapping survey. Mult Scler Relat Disord 27:171–178. https://doi.org/10.1016/j.msard.2018.09.032
doi: 10.1016/j.msard.2018.09.032 pubmed: 30384204
Portaccio E, Bellinvia A, Fonderico M et al (2022) Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain 145(8):2796–2805. https://doi.org/10.1093/brain/awac111
doi: 10.1093/brain/awac111 pubmed: 35325059
Ziemssen T, Hillert J, Butzkueven H (2016) The importance of collecting structured clinical information on multiple sclerosis. BMC Med 14:81. https://doi.org/10.1186/s12916-016-0627-1
doi: 10.1186/s12916-016-0627-1 pubmed: 27246898 pmcid: 4888646
MS International Federation. Putting people with MS at the heart of research. MS International Federation. Accessed January 17, 2023. https://www.msif.org/research/challenges-of-ms-research/ms-registries-putting-people-with-ms-at-the-heart-of-research/
Trojano M, Kalincik T, Iaffaldano P, Amato MP (2022) Interrogating large multiple sclerosis registries and databases: what information can be gained? Curr Opin Neurol 35(3):271–277. https://doi.org/10.1097/WCO.0000000000001057
doi: 10.1097/WCO.0000000000001057 pubmed: 35674068
AISM. Barometro sclerosi multipla Italia. Accessed July 12, 2022. https://agenda.aism.it/2022/
Brichetto G, Zaratin P (2020) Measuring outcomes that matter most to people with multiple sclerosis: the role of patient-reported outcomes. Curr Opin Neurol 33(3):295–299. https://doi.org/10.1097/WCO.0000000000000821
doi: 10.1097/WCO.0000000000000821 pubmed: 32324704 pmcid: 7259382
Alping P, Piehl F, Langer-Gould A, Frisell T (2019) Validation of the Swedish multiple sclerosis register. Epidemiol Camb Mass 30(2):230–233. https://doi.org/10.1097/EDE.0000000000000948
doi: 10.1097/EDE.0000000000000948
Magyari M, Joensen H, Laursen B, Koch-Henriksen N (2021) The Danish multiple sclerosis registry. Brain Behav 11(1):e01921. https://doi.org/10.1002/brb3.1921
doi: 10.1002/brb3.1921 pubmed: 33128351
AISM. Projects - Registro Italiano Sclerosi Multipla. Accessed July 13, 2022. https://registroitalianosm.it/index.php?page=progetticorrelati
Vollmer TL, Nair KV, Williams IM, Alvarez E (2021) Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol Clin Pract 11(4):342–351. https://doi.org/10.1212/CPJ.0000000000001045
doi: 10.1212/CPJ.0000000000001045 pubmed: 34476126 pmcid: 8382415
Iaffaldano P, Lucisano G, Guerra T et al (2022) Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: a study from the Italian MS register. Mult Scler Houndmills Basingstoke Engl 28(14):2243–2252. https://doi.org/10.1177/13524585221114007
doi: 10.1177/13524585221114007
Iaffaldano P, Lucisano G, Caputo F et al (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14:17562864211019574. https://doi.org/10.1177/17562864211019574
doi: 10.1177/17562864211019574 pubmed: 34104220 pmcid: 8170278
Concato J, Corrigan-Curay J (2022) Real-world evidence - where are we now? N Engl J Med 386(18):1680–1682. https://doi.org/10.1056/NEJMp2200089
doi: 10.1056/NEJMp2200089 pubmed: 35485775
Nelson EC, Dixon-Woods M, Batalden PB et al (2016) Patient focused registries can improve health, care, and science. BMJ 354:i3319. https://doi.org/10.1136/bmj.i3319
doi: 10.1136/bmj.i3319 pubmed: 27370543 pmcid: 5367618
Steinemann N, Kuhle J, Calabrese P et al (2018) The Swiss multiple sclerosis registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research. BMC Neurol 18(1):111. https://doi.org/10.1186/s12883-018-1118-0
doi: 10.1186/s12883-018-1118-0 pubmed: 30103695 pmcid: 6088400
Teljas C, Boström I, Marrie RA et al (2021) Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. Acta Neurol Scand 144(6):680–686. https://doi.org/10.1111/ane.13514
doi: 10.1111/ane.13514 pubmed: 34357597
Blaschke SJ, Ellenberger D, Flachenecker P et al (2022) Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. Mult Scler Houndmills Basingstoke Engl 28(6):865–871. https://doi.org/10.1177/13524585211039753
doi: 10.1177/13524585211039753

Auteurs

Paola Mosconi (P)

Laboratorio di Ricerca per il Coinvolgimento dei Cittadini in Sanità, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan, 20156, Italy. paola.mosconi@marionegri.it.

Tommaso Guerra (T)

Dipartimento Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università degli Studi Aldo Moro, Bari, Italy.

Pasquale Paletta (P)

Laboratorio di Ricerca per il Coinvolgimento dei Cittadini in Sanità, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan, 20156, Italy.

Antonio D'Ettorre (A)

Laboratorio di Ricerca per il Coinvolgimento dei Cittadini in Sanità, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan, 20156, Italy.

Michela Ponzio (M)

Scientific Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy.

Mario Alberto Battaglia (MA)

Scientific Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy.
Department of Physiopathology, Experimental Medicine and Public Health, University of Siena, Siena, Italy.

Maria Pia Amato (MP)

Centro Sclerosi Multipla AOU Careggi, Florence, Italy.

Roberto Bergamaschi (R)

Centro Interdipartimentale Sclerosi Multipla, Fondazione Istituto Neurologico C. Mondino, Pavia, Italy.

Marco Capobianco (M)

Centro Sclerosi Multipla, SC Neurologia, AO Santa Croce E Carle, Cuneo, Italy.

Giancarlo Comi (G)

Casa di Cura del Policlinico, Università Vita Salute San Raffaele, Milan, Italy.

Claudio Gasperini (C)

UOC di Neurologia e Neurofisiopatologia Azienda Ospedaliera S. Camillo-Forlanini, Rome, Italy.

Francesco Patti (F)

Centro Sclerosi Multipla AOU Policlinico Vittorio Emanuele, Catania, Italy.

Maura Pugliatti (M)

Centro di Servizio e Ricerca sulla Sclerosi Multipla, AOU di Ferrara, Ferrara, Italy.

Monica Ulivelli (M)

Dipartimento di Scienze Mediche Chirurgiche e Neuroscienze, Università degli Studi di Siena, Siena, Italy.

Maria Trojano (M)

Dipartimento Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università degli Studi Aldo Moro, Bari, Italy.

Vito Lepore (V)

Laboratorio di Ricerca per il Coinvolgimento dei Cittadini in Sanità, Dipartimento di Salute Pubblica, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milan, 20156, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH